NFKB1 and diffuse large B-cell lymphoma: ABC-subtype DLBCL is characterized by chronic active BCR signaling, constitutive MYD88 signaling, and subsequent NF-κB pathway, AKT/mTOR pathway, and interferon pathway activation15–17,29.